Nieto, Y., Nawaz, S. and Cagnoni, P.J. (1999) Overexpression of Her 2/Neu (H2N), but Not P53 Mutations Is a Poor Prognostic Factor of High-Risk Primary Breast Cancer (HRPBC) Treated With High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT). Proceedings of the American Society of Clinical Oncology.

has been cited by the following article:

• TITLE: Epidemiological Aspects of Metastatic Relapse of Breast Cancer in an African Context

  AUTHORS: Jean Marc Dia, Corneille Saki, Oyeladé Mouhideen, Eric Bohoussou, Moctar Touré, Gerard Okon, Privat Guié, Simplice Anongba

  KEYWORDS: Breast Cancer, Risk Factors, Metastatic Relapses

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.7 No.5, May 25, 2017

  ABSTRACT: Objectives: This study aimed to describe the epidemiological characteristics of metastatic relapse in breast cancer at the University and Hospital Center of Treichville. Methodology: This is a cohort and retrospective study conducted from January 2000 to December 2015 on 178 patients with metastaticrelapse in breast cancer. Results: The prevalence of metastatic relapses was 49% and the patients had an average age of 53.4 years and among them, 91.6% received school education and 88.2% did not have a high socioeconomic level. The majority of initial tumors were in Stage III (47.8%), SBR III (47.2%), High Ki 67 (46.5%), Negative RH (79.3%), and HER2 negative (58%). Metastases were generally unique (62.9%), dominated by bone sites (36.6%), with an average occurrencedelay of 2.4 years. After the occurrence of metastases, the cumulative survival rate was 5% at 3 years, and nil at 5 years. Conclusion: Metastatic relapses were common with poor prognosis.